Target expression details
| Target General Information | |||||
|---|---|---|---|---|---|
| Target ID | T71928 | ||||
| Target Name | CD antigen CD158a | ||||
| Synonyms | CD158 antigenlike family member A; Killer cell immunoglobulinlike receptor 2DL1; MHC class I NK cell receptor; NKAT1; Natural killerassociated transcript 1; p58 NK receptor CL42/47.11; p58 natural killer cell receptor clones CL42/47.11; p58.1 MHC classIspecific NK receptor; KIR2DL1 | ||||
| Target Type | Clinical Trial | ||||
| Gene Name | KIR2DL1 | ||||
| Biochemical Class | Immunoglobulin | ||||
| UniProt ID | KI2L1_HUMAN | ||||
| Target Gene Expression Profiles in the Disease-Relevant Drug Targeted Tissue of the Patients and Healthy Individuals | |||||
| Disease | Myeloma | ||||
| Example drug | mab 1-7F9 | Phase 2 | [530228], [530238], [1572592] | ||
| Tissue | Bone marrow | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.43 Z-score: -4.42 P-value: 2.29E-06 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Acute myelocytic leukemia | ||||
| Tissue | Bone marrow | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.32 Z-score: -0.63 P-value: 1.01E-12 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Target Gene Expression Profiles in Other Tissues of Healthy Individuals | |||||
|
|||||
| Reference | |||||
| Ref 530228 | Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009 Sep 24;114(13):2667-77. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.

